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Abstract
The mitochondrial protein, translocator protein (TSPO), is a widely used biomarker of neuroinflammation, but its non-
selective cellular expression pattern implies roles beyond inflammatory processes. In the present study, we investigated
whether neuronal activity modifies TSPO levels in the adult central nervous system. First, we used single-cell RNA
sequencing to generate a cellular landscape of basal TSPO gene expression in the hippocampus of adult (12 weeks old)
C57BL6/N mice, followed by confocal laser scanning microscopy to verify TSPO protein in neuronal and non-neuronal cell
populations. We then quantified TSPO mRNA and protein levels after stimulating neuronal activity with distinct stimuli,
including designer receptors exclusively activated by designer drugs (DREADDs), exposure to a novel environment and
acute treatment with the psychostimulant drug, amphetamine. Single-cell RNA sequencing demonstrated a non-selective and
multi-cellular gene expression pattern of TSPO at basal conditions in the adult mouse hippocampus. Confocal laser scanning
microscopy confirmed that TSPO protein is present in neuronal and non-neuronal (astrocytes, microglia, vascular endothelial
cells) cells of cortical (medial prefrontal cortex) and subcortical (hippocampus) brain regions. Stimulating neuronal activity
through chemogenetic (DREADDs), physiological (novel environment exposure) or psychopharmacological (amphetamine
treatment) approaches led to consistent increases in TSPO gene and protein levels in neurons, but not in microglia or
astrocytes. Taken together, our findings show that neuronal activity has the potential to modify TSPO levels in the adult
central nervous system. These findings challenge the general assumption that altered TSPO expression or binding
unequivocally mirrors ongoing neuroinflammation and emphasize the need to consider non-inflammatory interpretations in
some physiological or pathological contexts.
Introduction
The elucidation of neuroinflammatory mechanisms in psy-
chiatric and neurological disorders is a highly active area of
research that has the promise of establishing novel ther-
apeutic strategies beyond classical nosologic boundaries
[1–3]. Identifying and characterizing neuroinflammatory
processes requires the availability of suitable and reliable
biomarkers. Positron emission tomography (PET) using
radiolabeled ligands selective for the 18-kDa translocator
protein (TSPO) continues to be the most widely used
technique to assess putative neuroinflammatory processes
in-vivo [4–6]. TSPO is an evolutionarily conserved protein
localized in the outer mitochondrial membrane, which has
been linked to various (but not mutually exclusive) phy-
siological processes, including cholesterol transport and
steroid hormone synthesis, apoptosis and cell viability,
redox processes and oxidative stress, and mitochondrial
respiration and bioenergetics [4, 7]. Originally used to
detect discrete neurotoxic changes in the central nervous
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system (CNS) [8], TSPO has commonly turned into a bio-
marker of “neuroinflammation” or even “microglial acti-
vation” [9–11]. By contrast, the possibility that TSPO levels
could be altered by non-inflammatory stimuli is often
overlooked, especially by researchers and clinicians con-
centrating on neuroinflammatory mechanisms in psychiatric
and neurological disorders [4, 12]. This tendency may,
however, introduce substantial interpretative bias in inves-
tigations using the TSPO biomarker. Indeed, whereas
alterations in TSPO expression may have an inflammatory
origin in some pathological contexts, it may as well mirror
non-inflammatory processes in others [4].
Here, we examined neuronal TSPO levels under basal
conditions and after neuronal activation in several mouse
models. Whereas previous immunohistochemical studies
identified TSPO protein in neuronal precursor cells and
post-mitotic neurons [4, 13–15], it is currently unknown
whether neuronal activity modulates TSPO expression in
the brain. Based on the role of TSPO in mitochondrial
bioenergetics [16, 17], we hypothesized that TSPO
expression may mirror the increased demands in energy
production under conditions of increased neuronal activity,
and therefore, would be upregulated by the latter. To test
this hypothesis, we first used single-cell RNA sequencing
(scRNA-seq) to generate a cellular landscape of basal TSPO
gene expression in the hippocampus of adult mice, whereas
confocal laser scanning microscopy (CLSM) was used to
verify TSPO protein in neuronal and non-neuronal cell
populations. We then quantified TSPO mRNA and protein
after stimulating neuronal activity with distinct stimuli,
including designer receptors exclusively activated by
designer drugs (DREADDs), exposure to a novel environ-
ment and acute treatment with the psychostimulant drug,
amphetamine.
Methods
Animals
All experiments were performed using adult (12 weeks old)
male C57Bl6/N mice (Charles Rivers, Sulzfeld, Germany).
They were group-housed (4–5 animals per cage) in indivi-
dually ventilated cages (Allentown Inc., Bussy-Saint-
Georges, France) as described in detail elsewhere [18]. The
cages were kept in a specific-pathogen-free (SPF) holding
room, which was temperature- and humidity-controlled
(21 ± 3 °C, 50 ± 10%) and kept under a reversed light–dark
cycle (lights off: 09:00 AM–09.00 PM). All animals had ad
libitum access to standard rodent chow (Kliba 3336, Kai-
seraugst, Switzerland) and water throughout the entire
study. All procedures were conducted during the dark cycle
and had been previously approved by the Cantonal
Veterinarian’s Office of Zurich. All efforts were made to
minimize the number of animals used and their suffering.
The number of animals in each experimental condition and
series of experiment is summarized in Table S1 (Supple-
mentary Information). The sample sizes in each group were
estimated according to our previous studies exploring the
cellular sources of altered TSPO expression in mouse
models relevant to neuropsychiatric and neurodegenerative
disorders [12].
Single-cell RNA sequencing and analysis
Dissociation of hippocampal tissue and hippocampal cell
isolation was carried out using mechanical dissociation at 4
°C as described in Supplementary Information. Left and
right hippocampi from 3 animals were pooled for sub-
sequent scRNA-seq analysis.
The quality and concentration of the single-cell pre-
parations were evaluated using a haemocytometer in a Leica
DM IL LED microscope and adjusted to 1000 cells/μl.
10,000 cells were loaded into the 10X Chromium controller
and library preparation was performed according to the
manufacturer’s indications (single cell 3′ v3 protocol). The
resulting libraries were sequenced using the Illumina
NovaSeq sequencer according to a depth of ~50,000 reads
per cell. The scRNA-seq count matrix was analyzed using
the Seurat (v3) R package [19, 20]. The data were filtered to
include only cells from which expression was detected of
more than 500 and fewer than 2500 unique genes, and from
which fewer than 25% of the total counts were from
mitochondrial genes. Read counts were log-normalized
using a size factor of 10,000 molecules per cell and scaled
by linear transformation. Cell clustering was performed
using a dimensionality of 10 principle components and a
resolution of 0.6. Cell-type assignments were predicted by
matching representative expressed features to published cell
markers data [21]. Specific gene sets for cell-type identifi-
cation are provided in Fig. S1 (Supplementary Information).
The scRNAseq raw data files have been deposited at the
NCBI’s Gene Expression Omnibus [22] and are accessible
through GEO Series accession number GSE143796. Func-
tional network analyses were generated through the use of
Ingenuity Pathway Analysis (IPA) (QIAGEN, Redwood
City, CA, USA) as described before [23, 24].
Quantitative real-time polymerase chain reaction
(RT-PCR)
RNA extraction and quantitative RT-PCR analyses were
performed according to previously established protocols
[24, 25]. In brief, the animals were deeply anesthetized with
an overdose of Nembutal (Abbott 23 Laboratories, North
Chicago, IL, USA) and transcardially perfused with 20 ml
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ice-cold, artificial cerebrospinal fluid (CSF) (pH 7.4) [26].
After decapitation, the brains were immediately extracted
from the skull, frozen on dry ice and stored at −80 °C until
further processing. The brains were then cut into 1-mm
coronal brain sections using razorblade cuts and subsequent
micro-dissection of the medial prefrontal cortex (mPFC)
(bregma: +2.0 to +1.5 mm), hippocampus (Hpc) (bregma
−2.0 to −3.0 mm), nucleus accumbens (NAc) (bregma
+ 1.5 to +1.0 mm) and ventral midbrain (vMB) (bregma
− 3.0 and −3.5). Total RNA was isolated using the RNeasy
Plus Universal Mini Kit (Qiagen, Hilden, Germany). The
procedure was conducted according to the manufacturer’s
instructions, and the resulting RNA was quantified by the
Agilent 2200 BioAnalyzer (Agilent Technologies, Santa
Clara, USA). Quantitative RT-PCR was conducted with
iScript one-step RT-PCR kits and a Taqman real-time sys-
tem (CFX384, Bio-Rad Laboratories, Cressier, Switzerland)
as previously described [24, 25]. A mouse TaqMan gene
expression assay for TSPO (assay ID: Mm00437828_m1,
catalogue number: 4331182; Thermo Fisher Scientific,
Zurich, Switzerland) was used, whereas mRNA levels of
cFos, Arc and Zif268 were quantified using custom made
primers (Table S2 in Supplementary Information). Riboso-
mal phosphoprotein (36B4; Table S2 in Supplementary
Information) was used as the housekeeper control as vali-
dated previously [24, 25]. Relative gene expression was
calculated with the 2−ΔΔCt method [27]. All RT-PCRs and
analyses were conducted by an experimenter blind to the
experimental conditions. Blinding was performed in the
form of coding by numbers.
Immunohistochemistry and confocal microscopy
Immunofluorescence (IF) staining and CLSM were per-
formed according to previously established protocols
[12, 26]. In brief, the animals were perfused intracardially
with oxygenated artificial CSF (pH 7.4), followed by 12 h
post fixation in 4% phosphate-buffered paraformaldehyde
(PFA) and cryoprotection [12, 26]. The brain samples were
cut coronally with a sliding microtome at 30 μm (8 serial
sections) and stored at −20 °C in cryoprotectant solution
(50 mM sodium phosphate buffer (pH 7.4) containing 15%
glucose and 30% ethylene glycol; Sigma-Aldrich, Switzer-
land) until further processing. For IF staining, the slices
were rinsed with Tris buffer (pH 7.4) prior to incubation
with the primary antibody. A summary of all antibodies
used in this study is provided in Table S3 (Supplementary
Information). The primary antibodies were diluted in Tris
buffer containing 0.2% Triton X-100 and 2% normal serum,
and the sections were incubated free-floating under constant
agitation (100 rpm) overnight at 4 °C. The sections were
then washed three times for 10 min in Tris buffer, incubated
for 30 min at room temperature with secondary antibodies
coupled to either Alexa488 (diluted 1:1000; Molecular
Probes, Eugene, USA), Alexa568 or Alexa647 (each diluted
1:500; Jackson ImmunoResearch, Ely, UK) and DAPI
(1 mg/mL H2O; Thermo Fisher Scientific, Zurich, Switzer-
land; diluted 1:20’000) Jackson ImmunoResearch, Ely,
UK). After incubation, which was shielded from light, the
sections were washed thoroughly three times for 10 min in
Tris buffer, mounted onto gelatinized glass slides, cover-
slipped with Dako fluorescence mounting medium and
stored in the dark at 4 °C. Data collection was performed
with a confocal laser scanning microscope (LSM-700;
Zeiss, Jena, Germany) as described in Supplemen-
tary Information. TSPO intensities co-localized with neu-
rons, microglia, or astrocytes were measured and calculated
using a custom macro (kindly provided by Prof. Jean-Marc
Fritschy, Institute of Pharmacology and Toxicology, Uni-
versity of Zurich, Switzerland) for the ImageJ software. A
detailed description of how TSPO co-localization was
quantified is provided in Supplementary Information. All IF
stainings and the corresponding analyses were performed
by an experimenter blind to the experimental conditions.
Blinding was performed in the form of coding by numbers.
DREADD system
A DREADD-based chemogenetic approach was used to
examine whether TSPO mRNA and protein levels change in
response to selective neuronal activation. The following
adeno-associated viruses (AAVs) were used: AAV8-hSyn1-
hM3D(Gq)-mCherry (hM3DGqV) and AAV8-hSyn1-EGFP
(ConV). They were purchased from the Viral Vector Facility
of the University of Zurich, Switzerland (www.vvf.uzh.ch)
and were injected unilaterally in the medial prefrontal cortex
(mPFC; anteroposterior [AP]=+2.0 mm, mediolateral
[ML]=+0.3 mm, dorsoventral [DV]=− 2.0 mm, with
reference to bregma) or the dorsal hippocampus (Hpc; AP=
−2.0, ML=+1.6, DV=−1.9, with reference to bregma)
using stereotaxic surgery. The latter was performed as
described in Supplementary Information.
After a 2 weeks recovery period, the animals were
injected with clozapine-N-oxide (CNO, 1 mg/kg; Enzo Life
Sciences, Lausen, Switzerland) dissolved in 0.9% NaCl (B.
Braun, Melsungen, Switzerland) or with 0.9% NaCl vehicle
(Veh) solution only. The dose of CNO (1 mg/kg, i.p.) was
chosen based on previous chemogenetic studies in rodents
[28–30]. All substances were injected intraperitoneally (i.p.)
using an injection volume of 5 ml/kg. After CNO or Veh
injections, the animals were placed back into their home
cages and killed 90 min (gene expression analyses) or 180
min (protein expression analyses) after injections as
described above.
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Environmental and psychopharmacological
manipulations
To study TSPO mRNA and protein levels following neuro-
nal activation under physiological conditions, we compared
animals exposed to a novel environment (NovE) and animals
kept in their familiar home cage (HC). The NovE was a wall-
enclosed open field arena (40 × 40 × 35 cm high) made of
white polyvinyl chloride (PVC), which contained numerous
unfamiliar objects (green LEGO® DUPLO® 2 × 4 brick, 64 ×
32 × 24mm3; black acrylic cylinder, 200 mm height, 50 mm
diameter; transparent glass bottle, height 130 mm). In addi-
tion, the open field arena contained visual cues (black objects
printed on white background), which were positioned on the
arena’s inner walls. The animals were gently placed into the
center of the arena and allowed to freely explore for 15min,
after which they were returned to their home cages before
sacrificed 90min (gene expression analyses) or 180 min
(protein expression analyses) thereafter.
To study TSPO expression after psychopharmacological
manipulations, we compared animals treated with saline
(Sal; isotonic 0.9% NaCl) or D-amphetamine sulfate (Amph;
Sigma-Aldrich, Switzerland) solution. Amph was dissolved
in Sal solution and was administered at a dose of 2.5 mg/kg
(i.p.) based on our previous studies [31]. All solutions were
freshly prepared on the day of administration and were
injected using an injection volume of 5 ml/kg. The animals
were sacrificed for subsequent mRNA analyses (see above)
90 min after Sal or Amph treatment. The hypolocomotor
response to the Amph challenge was confirmed by mea-
suring the animals’ locomotor activity in an open field arena
using the EthoVision (Noldus Technology, Wageningen,
The Netherlands) tracking system as described before [31].
Statistical analyses
A standard Seurat (v3) R workflow [20] was used for
clustering and visualization of the scRNA-seq data, which
included data scaling, principal component analysis and
reduction, t-distributed stochastic neighbor embedding
(tSNE), and uniform manifold approximation and projec-
tion (UMAP) clustering. Differential gene expression ana-
lysis in the scRNA-seq dataset was carried out using
FindMarker functions, and p-values were calculated using
Wilcoxon Rank Sum test with Bonferroni correction.
All RT-PCR and IF data met the assumptions of normal
distribution and equality of variance. They were analyzed
using independent Student’s t-test (two-tailed), whereas
locomotor activity in the open field after Amph or Sal
treatment was analyzed using a 2 × 18 (treatment × 5-min
bins) repeated-measures analysis of variance (RM-
ANOVA). These analyses were performed using SPSS
Statistics (version 25.0, IBM, Armonk, NY, USA), with
statistical significance set at P < 0.05 for all analyses.
Exclusion of animals was not applied.
Results
Cellular landscape of basal TSPO expression in the
mouse hippocampus
First, we obtained scRNA-seq of hippocampal cell sus-
pensions from adult C57BL6/N mice in order to generate a
landscape of basal TSPO mRNA expression in non-
neuronal and neuronal cell populations. Clustering using
specific gene-set enrichment for cell-type identification
revealed 9 main cell populations (Fig. 1a; Fig. S2 in Sup-
plementary Information), which could be broken down
further into 18 clusters containing distinct cell sub-
populations (Fig. S3 in Supplementary Information). As
expected [12, 14, 15], basal TSPO mRNA expression was
most abundant in ependymal cells, vascular endothelial
cells and microglia (Fig. 1b, c). Detectable TSPO mRNA
levels were, however, present in all other hippocampal cell
populations as well, including neurons (Fig. 1b, c). Whilst
~3% of all neuronal cells were positive for TSPO mRNA
(Fig. 1b, c), individual neuronal sub-populations showed a
different TSPO mRNA expression profile (Fig. 1d). In three
out of four neuronal sub-clusters (neuronal sub-cluster 1/2/
4), TSPO mRNA was measurable in only 1.0 to 1.7% of
cells, whereas TSPO mRNA was detected in 7.5% of cells
in the remaining neuronal sub-cluster (neuronal sub-cluster
3) (Fig. 1d). Subsequent IPA of differentially expressed
genes (neuronal sub-cluster 3 versus sub-clusters 1/2/4)
demonstrated that the sub-cluster with higher TSPO mRNA
expression (i.e., neuronal sub-cluster 3) was characterized
by increased expression of genes involved in the eukaryotic
initiation factor 2 (EIF2) signaling pathway (z-score= 6.16,
−log(p-value)= 48.8; Fig. 1e). Consistent with the role of
TSPO in mitochondrial bioenergetics [16, 17], neuronal
sub-cluster 3 with high TSPO mRNA expression also
showed high levels of gene expression pertaining to oxi-
dative phosphorylation (z-score= 3.74, -log(p-value)= 4.8;
Fig. 1e). Taken together, scRNA-seq confirmed the multi-
cellular expression profile of TSPO under basal conditions
and further showed that TSPO mRNA is detectable in
various neuronal cell populations with a varying degree of
basal gene expression.
We further analyzed TSPO protein levels in neuronal and
non-neuronal cells of the cornu ammonis by means of IF
staining analyzed by CLSM, thereby using an antibody
whose specificity was previously verified in a viable TSPO
knockout mouse model [32]. In neurons, TSPO protein was
found to co-localize with several post-mitotic neuronal
markers, including neuronal nuclei (NeuN), neurofilament
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heavy polypeptide (SMI-32) and microtubule-associated
protein 2 (MAP-2) (Fig. 2a) in hippocampal sections from
adult (12 weeks old) C57BL6/N mice. The same CLSM
analyses of IF staining also detected TSPO protein in non-
neuronal cells, including microglia, astrocytes and vascular
endothelial cells (Fig. 2b). Consistent with its mitochondrial
localization, TSPO immunoreactivity generally appeared as
defined punctae in both neuronal and non-neuronal cell
types (Fig. 2). These data confirm that TSPO protein is
present in both neuronal and non-neuronal cell populations
under basal conditions.
TSPO expression after selective neuronal activation
We next examined whether TSPO mRNA and protein levels
change in response to selective neuronal activation. To this
Fig. 1 Cellular landscape of basal TSPO expression in the hippo-
campus of adult mice. a Visualization of single-cell RNA-sequencing
(scRNA-seq) data using t-distributed stochastic neighbor embedding
(tSNE), showing the clustering of 9 main cell populations. Cellular
sub-clusters are provided in Fig. S3 (Supplementary Information).
Corresponding uniform manifold approximation and projection
(UMAP) scores are shown in Figure S2 (Supplementary Information).
b TSPO expression (in red) in individual clusters of cells as detected
by scRNA-seq. c Percentage of cells expressing TSPO in each of the 9
main cell populations, as measured by scRNA-seq. d tSNE scores of
neuronal sub-clusters (neuronal clusters 1–4) and percentage of cells
expressing TSPO in each of the 4 neuronal sub-clusters. e Differential
gene expression (indexed as average log2 fold change, Log2FC)
between neuronal cluster 3 and neuronal cluster 1/2/4, showing dif-
ferentially expressed genes included in the eukaryotic initiation factor
2 (EIF2) signaling pathway and oxidative phosphorylation as identi-
fied by Ingenuity Pathway Analysis (IPA). The significance of dif-
ferential gene expression is given as –Log10(p-value).
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aim, we first used a DREADD-based chemogenetic
approach [28], in which we targeted mPFC neurons of adult
mice via unilateral stereotactic injections of a recombinant
AAV that expresses the modified human muscarinic M3 G-
protein-coupled (Gq) receptor under the control of the
human synapsin-1 promoter (hM3DGqV) (Fig. 3a). This
excitatory receptor was then activated by CNO (1 mg/kg,
i.p.) [29, 30], leading to the selective activation of neurons.
To control for possible off-target effects of CNO [33, 34],
we compared CNO (relative to Veh) treatment in mice
injected with hM3DGqV and mice injected with a recom-
binant control AAV expressing a reporter gene under the
same synapsin-1 promoter (ConV). As expected [28, 35],
CNO treatment in hM3DGqV-injected mice led to robust
neuronal activation, as evident by the significant increase in
the mRNA levels of several neuronal activity markers,
including cFos (t(12)= 4.90, P < 0.001), Arc (t(12)= 4.63, P
< 0.001) and Zif268 (t(12)= 4.35, P < 0.001) (Fig. 3b). CNO
treatment in hM3DGqV-injected mice similarly increased
TSPO mRNA levels (t(12)= 4.29, P < 0.001; Fig. 3b), sug-
gesting that selective activation of mPFC neurons increases
TSPO gene expression. Importantly, CNO treatment alone
in ConV-injected mice had no effect on the mRNA levels of
neuronal activity markers or TSPO (Fig. 3b). Hence, the
CNO-mediated increase in TSPO mRNA expression, which
was specifically observed in hM3DGqV-injected mice, is
unlikely to be accounted for by possible off-target effects of
CNO, but rather arises from genuine DREADD-mediated
neuronal activation.
We then used CLSM of IF-stained brain sections to
explore whether DREADD-mediated neuronal activation
also changes TSPO protein in the mPFC. The intensity of
TSPO co-localizing with NeuN-positive neurons was sig-
nificantly increased in the mPFC of hM3DGqV-injected
mice after CNO relative to Veh treatment (t(10)= 3.65, P <
0.01; Fig. 3c). By contrast, CNO treatment did not alter the
intensity of TSPO protein co-localizing with Iba1-positive
microglia or GFAP-positive astrocytes. Consistent results
were obtained in the Hpc of adult mice. Indeed, when
applying the DREADD-based model of neuronal activation
to the adult Hpc (Fig. 3d), a similar increase in TSPO
protein in NeuN-positive Hpc neurons emerged after CNO
treatment (relative to Veh treatment) in hM3DGqV-injected
mice (t(10)= 3.59, P < 0.01; Fig. 3e). Taken together, these
Fig. 2 Immunohistochemical localization of TSPO protein in
neuronal and non-neuronal hippocampal cells of adult mice using
immunofluorescence staining analyzed by confocal laser scanning
microscopy. The photomicrographs show representative Z-stack
images acquired through confocal microscopy, with nuclear staining
(DAPI) in blue, TSPO in green and various CNS cells of interest in
red. TSPO co-localizing with the cellular markers of interest appears in
yellow. Examples of co-localization areas are highlighted by the
crosshair. a Examples of neuronal TSPO protein expression, as eval-
uated using the post-mitotic neuronal markers NeuN, SMI-32 and
MAP-2. b Examples of non-neuronal TSPO protein expression,
including expression in Iba1-positive microglia, GFAP-positive
astrocytes and Glut1-positive vascular endothelial cells.
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data demonstrate that enhancing neuronal activity in cortical
(mPFC) or subcortical (Hpc) regions increases TSPO levels
in neurons but not in glial cells.
TSPO expression after neuronal activation under
physiological and psychopharmacological
conditions
We next explored whether TSPO expression also changes in
response to neuronal activation induced by physiological
and psychopharmacological manipulations. To assess the
former, we compared neuronal activity markers as well as
TSPO mRNA and protein levels in the Hpc of adult mice
that were briefly (15 min) exposed to a novel environment
(NovE), relative to mice that were kept in their familiar
home cage (HC) environment (Fig. 4a). As expected [36],
exposure to NovE stimulated neuronal activity in the Hpc,
as evident by the significant increase in the mRNA levels of
cFos (t(14)= 4.48, P < 0.001), Arc (t(14)= 3.12, P < 0.01)
and Zif268 (t(14)= 2.99, P < 0.01) (Fig. 4b). Exposure to
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NovE also increased TSPO mRNA levels in the Hpc (t(14)=
2.80, P < 0.05; Fig. 4b), showing that hippocampal TSPO
gene expression parallels NovE-mediated activation of Hpc
neurons. Subsequent CLSM analyses of IF-stained hippo-
campal sections confirmed this notion, showing that expo-
sure to NovE increases the intensity of TSPO protein co-
localizing with NeuN-positive neurons of the cornu
ammonis (Fig. 4c). By contrast, exposure to NovE did not
alter TSPO protein levels co-localizing with Iba1-positive
microglia or GFAP-positive astrocytes in this brain area
(Fig. 4c).
Finally, we investigated whether acute treatment with
Amph, a psychostimulant drug that increases central
dopamine and norepinephrine release [37], modulates the
expression of TSPO. To this aim, we focused on the tran-
scriptional activity of TSPO in two dopaminergic brain
areas activated by Amph exposure, namely the NAc and
vMB (Fig. 4d). As expected [31, 38], systemic Amph
(2.5 mg/kg, i.p.) treatment enhanced locomotor activity
(main effect of treatment in RM-ANOVA: F(1,16)= 28.80,
P < 0.001; Fig. 4e) and increased the mRNA levels of the
neuronal activity marker, cFos, in both the NAc (t(16)=
4.56, P < 0.001) and vMB (t(16)= 3.27, P < 0.01) (Fig. 4f).
Amph treatment also increased TSPO mRNA in both brain
areas (NAc: t(16)= 3.12, P < 0.01; vMB: t(16)= 3.09, P <
0.01; Fig. 4f). Together, these findings demonstrate the
capacity of physiologically or psychopharmacologically
induced neuronal activation to upregulate TSPO mRNA and
protein in the adult CNS.
Discussion
The present study examined neuronal TSPO expression
under basal conditions and after neuronal activation in
several mouse models. In line with the qualitative findings
from previous immunohistochemical studies [4, 14, 15],
scRNA-seq analysis and CLSM of IF-stained brain sections
identified relatively low but clearly detectable TSPO mRNA
and protein in neurons under basal conditions. To our
knowledge, the present scRNA-seq analysis of TSPO
mRNA is the first to take into account the entire spectrum of
hippocampal cells in adult mice. This analysis provided an
unbiased approach of comparing basal TSPO gene expres-
sion in different hippocampal cell populations, and as such,
it corroborates the existing evidence of the multi-cellular
expression profile of TSPO [4, 14, 15, 39, 40]. This non-
selective cellular expression pattern is not unprecedented,
given that TSPO is a mitochondrial protein with various
plausible functions pertaining to a number of CNS cell
types [16, 17, 32, 41].
We further identified neuronal activation to represent a
novel non-inflammatory mechanism by which TSPO levels
can be altered in the brain. Indeed, we found consistent
increases in TSPO gene expression and protein levels after
neuronal activation using a spectrum of stimuli, including
selective stimulation (DREADD system), physiological
activation (NovE exposure) and psychopharmacological
manipulation (Amph treatment). These data provide the first
direct evidence for a causal relationship between neuronal
activity and TSPO levels in the CNS. The fact that these
effects involved increases in TSPO mRNA further implies
de-novo synthesis of TSPO in response to neuronal stimu-
lation. Moreover, neuronal activation upregulated TSPO
selectively in neurons, but not in in glial cells, pointing
toward specific neuronal effects.
On speculative grounds, neuronal activity may lead to
higher TSPO levels in neurons because of increased energy
demands. Circumstantial evidence for this hypothesis stems
from previous findings implicating TSPO in mitochondrial
bioenergetics and ATP production [16, 17]. This hypothesis
is also consistent with our scRNA-seq analysis, demon-
strating that basal TSPO expression in neurons is highest in
those neuronal sub-populations that are characterized by
Fig. 3 Increased TSPO levels following selective neuronal activa-
tion using the DREADD system in adult mice. a Schematic illus-
tration and verification of the experimental approach. Mice were
subjected to unilateral stereotactic injections of recombinant AAV
expressing the modified human muscarinic M3 G-protein-coupled
receptor under the control of the human synapsin-1 promoter
(hM3DGqV), or recombinant control AAV expressing a reporter gene
under the same synapsin-1 promoter (ConV), into the medial pre-
frontal cortex (mPFC). Gene expression was assessed 90 min after
vehicle (Veh) or clozapine-N-oxide (CNO, 1 mg/kg, i.p.) treatment,
whereas protein expression was assessed 180 min post-treatment. The
photomicrograph shows representative hM3DGqV expression in the
injected mPFC hemisphere. b mRNA levels of cFos, Arc, Zif268 and
TSPO (as measured by quantitative polymerase chain reaction) in the
mPFC of ConV- or hM3DGqV-injected mice 90 min after treatment
with Veh or CNO. c Intensity (relative optical density) of TSPO
protein co-localizing with NeuN-positive neurons (left), Iba1-positive
microglia (middle) and GFAP-positive astrocytes in the mPFC of
hM3DGqV-injected mice 180 min after treatment with Veh or CNO
(1 mg/kg, i.p.). The photomicrographs show representative images
acquired through confocal microscopy, with nuclear staining (DAPI)
in blue, TSPO in green and cell types of interest (neurons, microglia
and astrocytes) in red. TSPO co-localizing with the cellular markers of
interest appears in yellow. d Schematic illustration and immunohis-
tochemical verification of unilateral, stereotactic injections of recom-
binant AAV expressing hM3DGqV into the hippocampus (Hpc). The
photomicrographs show representative confocal images of hM3DGqV-
injected mice at the level of the CA1 region of the Hpc, 180 min after
treatment with Veh or CNO. Note the induction of cFos protein levels
(in green) in CNO-treated relative to Veh-treated mice. e Intensity
(relative optical density) of TSPO protein co-localizing with NeuN-
positive neurons in the Hpc of hM3DGqV-injected mice 3 h after
treatment with Veh or CNO (1 mg/kg, i.p.). The photomicrographs
show representative images acquired through confocal microscopy,
with nuclear staining (DAPI) in blue, TSPO in green and NeuN in red.
TSPO co-localizing with the cellular markers of interest appears in
yellow. For all data, **P < 0.01 and ***P < 0.001; each dot in the
scatter plot represents an individual animal.
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transcriptional indices of increased protein synthesis and
oxidative phosphorylation. More specifically, we found
higher TSPO mRNA levels in a neuronal sub-population
showing increased expression of genes involved in
EIF2 signaling pathway, which in turn is essential for
initiating the translation and protein synthesis in neurons
[42]. Consistent with the role of TSPO in mitochondrial
bioenergetics [16, 17], this neuronal sub-cluster also
showed increased expression of genes involved in oxidative
phosphorylation. Hence, the extent to which neuronal TSPO
is expressed under basal conditions appears to parallel the
transcriptional activity of neurons, which in turn may raise
the cellular demand in oxidative phosphorylation and sub-
sequent energy production.
This hypothesis may also explain why under basal con-
ditions TSPO mRNA is generally more abundant in epen-
dymal cells, vascular endothelial cells and microglia than in
neurons. Indeed, these non-neuronal cell types are char-
acterized by marked energy demands, even under non-
pathological or homeostatic conditions. For example,
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ependymal cells are a specialized type of epithelial cells that
line the ventricular system of the brain and play a key role
in the homeostasis of CSF [43]. They possess a large
number of mitochondria, which are required to meet the
energy demand of ependymal cells for CSF transport and
other homeostatic processes [44]. Therefore, it appears
logically consistent that the sqRNA-seq analysis identified
ependymal cells to be the cell population with the most
abundant TSPO transcripts. Likewise, microglia are now
known to be “never-resting cells” that constantly survey the
CNS for invading pathogens, changes in the physiological
microenvironment and/or CNS injury [45, 46]. The sur-
veying activities of microglia arguably require energy,
which may be readily mirrored by the abundance of TSPO
transcripts, even under non-pathological, homeostatic con-
ditions. Upon activation by pathological insults, microglia
rapidly alter their morphological appearance and transcrip-
tional profiles, increase their motility and phagocytic
activity and produce and secrete various factors that are
integral for combating pathogens and/or initiating and
promoting tissue remodeling and repair. All of these
responses require additional energy and corresponding
adaptations in mitochondrial bioenergetics [47, 48], such
that the upregulation of TSPO in microglia under patholo-
gical conditions [4–6] may generally reflect the cells’
increased demand in energy production. If confirmed by
future investigations, the upregulation of neuronal TSPO in
response to neuronal activation may reflect similar bioe-
nergetic processes.
It is currently unknown whether altered neuronal activity
may contribute to changes in TSPO binding as observed in
PET studies of neurological and psychiatric disorders.
Several recent findings suggest, however, that this possibi-
lity may indeed exist. In a cohort of long-term cannabis
users and control subjects, for example, Da Silva et al. [49]
found a positive correlation between TSPO levels and states
of stress and anxiety, both of which have stimulatory effects
on limbic neurons [50]. Combining TSPO PET imaging
with proton magnetic resonance spectroscopy further
revealed a positive association between TSPO binding and
the levels of γ-aminobutyric acid (GABA) in the mPFC of
people at clinical high risk for psychosis and healthy
volunteers [51]. Even though a direct neuronal contribution
to altered TSPO expression or binding in psychosis still
awaits verification, these findings are in line with the notion
that glial cells are unlikely to be the sole cellular sources
underlying these changes [4, 12, 52]. In fact, given our
findings presented here, the prefrontal downregulation of
TSPO occurring in a subset of patients with psychotic dis-
orders [12] and in disease-relevant animal models [53] may,
at least in part, reflect reduced neuronal activity in PFC
structures or “hypofrontality”. Finally, it has recently been
found that the variable cortical burden of TSPO does not
correlate with the burden of activated microglia or reactive
astrocytes in the brains of late-stage Alzheimer’s disease
patients [54]. Future studies will be necessary to determine
whether loss of neurons and/or blunted neuronal activity
may contribute to reduced TSPO expression occurring in a
substantial portion of patients with late-stage Alzheimer’s
disease or Lewy body dementia [54].
We appreciate that our study has a number of limitations.
First, because of ethical and technical reasons, we investi-
gated the relationship between neuronal activity and TSPO
levels in mouse models only. Therefore, we cannot rule out
possible species differences, which are relevant in the
context of inflammatory regulation of TSPO expression in
microglia and macrophages [55]. Second, we included mice
of one sex (males) and age (early adulthood) only. In view
of the recently identified influence of sex [56] and age
[56, 57] on brain TSPO expression, additional studies are
warranted to explore whether our findings are generalizable
across sex and different ages.
Despite these limitations, we conclude that our findings
have important implications for implementing and inter-
preting TSPO-based biomarker studies. TSPO is commonly
used as a biomarker of neuroinflammation in general, and of
microglial activation in particular [9–11]. However while
TSPO-based PET imaging signals have often been
Fig. 4 Increased TSPO levels following neuronal activation under
physiological and psychopharmacological conditions in adult mice.
a Schematic illustration of the experimental design used to assess
TSPO levels after neuronal activation under physiological conditions.
Mice were exposed to a novel environment (NovE) for 15 min. Gene
expression was then assessed 90 min after NovE exposure, whereas
protein expression was assessed 180 min post-exposure. Control mice
were kept in their familiar home cage (HC) environment. b mRNA
levels of cFos, Arc, Zif268 and TSPO (as measured by quantitative
polymerase chain reaction) in the hippocampus 90 min after NovE
exposure, relative to mice kept in the HC environment. c Intensity
(relative optical density) of TSPO protein co-localizing with NeuN-
positive neurons (left), Iba1-positive microglia (middle) and GFAP-
positive astrocytes in the Hpc 180 min after NovE exposure, relative to
mice kept in the HC. The photomicrographs show representative
images acquired through confocal microscopy, with nuclear staining
(DAPI) in blue, TSPO in green and cell types of interest (neurons,
microglia and astrocytes) in red. TSPO co-localizing with the cellular
markers of interest appears in yellow. d Schematic illustration of the
experimental design used to assess TSPO expression after neuronal
activation under psychopharmacological conditions. Mice were
injected with saline (Sal) or amphetamine (Amph, 2.5 mg/kg, i.p.) and
then placed into an open field to verify Amph-induced hyperloco-
motion. Gene expression was evaluated in the nucleus accumbens
(NAc) and ventral midbrain (vMB) 90 min after Sal or Amph
administration. e Distances moved after Sal or Amph administration as
a function of 5-min bins. ***P < 0.001, based on repeated-measures
ANOVA. f mRNA levels of cFos and TSPO (as measured by quan-
titative polymerase chain reaction) in the NAc and vMB 90 min after
administration of Sal or Amph. *P < 0.05, **P < 0.01 and ***P <
0.001, based on two-tailed Student’s t-test; each dot in the scatter plot
represents an individual animal.
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considered to support neuroinflammatory theories of disease
[9–11], it appears difficult, if not impossible, to define the
precise pathophysiological meanings and cellular sources of
altered TSPO binding in such studies. In some pathological
conditions, increased TSPO expression may primarily
reflect ongoing inflammatory processes [58–60], whereas in
others it may signify anomalies in cellular metabolism and
energy production [17], oxidative stress [61], and/or neu-
ronal activity (present findings). The ambiguity of con-
ceiving TSPO simply as a biomarker of neuroinflammation
or microglial activation warrants caution, and supports the
urgent development of novel approaches for assessing
changes in inflammatory states in the brain [4, 62, 63].
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